ASTR

Postresection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 World Health Organization classification: single-center experience of 168 patients

Minjae Kim¹, Shin Hwang¹, Chul-Soo Ahn¹, Ki-Hun Kim¹, Deok-Bog Moon¹, Tae-Yong Ha¹, Gi-Won Song¹, Dong-Hwan Jung¹, Gil-Chun Park¹, Seung-Mo Hong²

¹Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea ²Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Purpose: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) has wide histologic diversity. This study investigated the effects of cHCC-CC histology, according to the 2010 World Health Organization (WHO) classification, on patient prognosis.

Methods: The medical records of patients who underwent surgical resection for cHCC-CC at our institution between July 2012 and June 2019 were retrospectively evaluated.

Results: During the study period, 168 patients, 122 males (72.6%) and 46 females (27.4%), underwent surgical resection for cHCC-CC, including 159 patients (94.6%) who underwent R0 resection. Mean tumor diameter was 4.4 ± 2.8 cm, and 161 patients (95.8%) had solitary tumors. Histologically, 86 patients (51.2%) had classical type, and 82 (48.8%) had tumors with stem cell (SC) features, including 33 (19.6%) with intermediate-cell and 23 (13.7%) each with typical SC and cholangiolocellular features; 3 tumors (1.8%) were unclassifiable. At 1, 3, and 5 years, tumor recurrence rates were 31.9%, 49.6%, and 58.1%, respectively, and patient survival rates were 91.0%, 70.2%, and 60.3%, respectively. Univariate analysis showed that tumor size of >5 cm, microscopic and macroscopic vascular invasion, lymph node metastasis, 8th edition of the American Joint Committee on Cancer (AJCC) tumor stage, and 2010 WHO classification were significantly prognostic. Multivariate analysis showed that the 8th AJCC tumor stage and 2010 WHO histologic classification were independently prognostic for tumor recurrence and patient survival. There were no significant prognostic differences among the 3 SC subtypes.

Conclusion: Postresection outcomes are better in patients with SC-type than with classical-type cHCC-CC. **[Ann Surg Treat Res 2021;100(5):260-269]**

Key Words: Combined tumor, Hepatic, Hepatocellular carcinoma, Progenitor cells, Stem cells

INTRODUCTION

Combined hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CC) is an uncommon type of primary liver

cancer, first described as a distinct disease entity in 1903. This tumor was first classified in 1949 [1] and again in 1985 [2]. The third classification, by the World Health Organization (WHO) in 2010, categorized this tumor according to its origin from

Received October 5, 2020, Revised January 21, 2021, Accepted February 16, 2021

Corresponding Author: Shin Hwang

Department of Surgery, Asan Medical Center, Olympic-ro 43-gil 88, Songpa-gu, Seoul 05505, Korea **Tel:** +82-2-3010-3930, **Fax:** +82-2-3010-6701 **E-mail:** shwang@amc.seoul.kr **ORCID:** https://orcid.org/0000-0002-9045-2531 Copyright © 2021, the Korean Surgical Society

© Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

hepatic progenitor cells (HPCs) [3]. Thus, combined HCC and CC (cHCC-CC) can be classified into 2 main histological forms, the classical type and subtypes with stem cell (SC) features.

We have previously evaluated the association between pathological characteristics and postresection prognosis of patients with cHCC-CC according to the 2010 WHO classification [4]. Because of the low incidence of cHCC-CC and the relatively recent adoption of the 2010 WHO classification, only a few studies to date have evaluated the pathology-based prognosis of these patients following hepatic resection (HR) [3-7]. The present study investigated the clinical and pathological features, as determined by the 2010 WHO classification, and the postresection outcomes of patients with cHCC-CC who underwent HR.

METHODS

Patients

We searched the liver cancer database of our institution to identify patients with cHCC-CC who were diagnosed according to the 2010 WHO classification from July 2012 to June 2019. Of the 6,504 patients who underwent HR for HCC and intrahepatic CC (ICC) in our institution during the study period [8], 179 (2.8%) underwent HR for cHCC-CC. Patients who had HCC and cHCC-CC concurrently, and those who underwent R2 resection, were excluded. Finally, 168 patients were selected for this study; all were followed up until July 2020 through a review of institutional medical records and with the assistance of the National Health Insurance Service. The study protocol was approved by the Institutional Review Board of Asan Medical Center (No. 2019-1347), which waived the requirement for informed consent due to the retrospective nature of this study. This study was performed in accordance with the ethical guidelines of the World Medical Association Declaration of Helsinki 2013.

Histologic diagnosis according to the 2010 WHO classification

Tumors were categorized as the classical type and as subtypes with SC features based on the 2010 WHO classification [3]. Tumors with SC features were subclassified as typical, intermediate-cell, and cholangiolocellular subtypes. The typical subtype was defined as tumors with a nest of mature hepatocytes surrounded by peripheral clusters of small cells exhibiting morphological and immunohistochemical characteristics of progenitor cells; the intermediate-cell subtype was defined as tumors containing cells with features intermediate between hepatocytes and cholangiocytes, with immunohistochemical markers of both arranged in trabeculae, solid nests, or strands. The cholangiolocellular subtype was defined as tumors composed of cells morphologically mimicking cholangioles arranged in a tubular anastomosing pattern within a dense, sclerotic stroma and expressing progenitor/SC markers.

Tumors were classified into subtypes based on the results of immunohistochemical staining for α -FP, CEA, cytokeratin 7, cytokeratin 19, epithelial cell adhesion molecule (EpCAM), HepPar1, CD10, CD34, KIT (CD117), nuclear cell adhesion molecule (NCAM1/CD56), reticulin, and others [3]. A small number of tumors with SC features could not be immunohistochemically characterized into one of these 3 subtypes and were therefore defined as being of unclassifiable subtype.

Tumor staging according to the 8th edition of the American Joint Committee on Cancer staging system

All cHCC-CCs were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for ICC because this staging system was found to be equally valid for ICCs, cHCC-CCs, and primary endocrine tumors of the liver [9]. T1 stage is defined as a solitary tumor without vascular invasion (T1a \leq 5 cm and T1b > 5 cm); T2 stage includes solitary tumors with vascular invasion or multiple tumors; T3 stage is defined as penetration of the visceral peritoneum; and T4 stage is defined as direct invasion of extrahepatic structures.

Statistical analysis

We analyzed the continuous variables by using Student t-tests or analysis of variance depending on their distribution. We compared the categorical variables by using the chi-square test or Fisher exact test. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression analysis was used to calculate hazard ratios and 95% confidence intervals. Statistical analyses were performed using IBM SPSS ver. 22 (IBM Corp., Armonk, NY, USA), with P-values of <0.05 regarded as statistically significant.

RESULTS

Clinicopathological features

The clinical features of the 168 patients pathologically diagnosed with cHCC-CC are summarized in Table 1. These patients included 122 males (72.6%) and 46 females (27.4%), with mean age of 56.6 ± 10.7 years (range, 30-81 years). Most patients had been preoperatively diagnosed with HCC, with 19 (11.3%) initially undergoing transcatheter arterial chemoembolization (TACE) and 1 (0.6%) undergoing radiofrequency ablation.

Of these 168 patients, 159 (94.6%) underwent R0 resection and 9 (5.4%) underwent R1 resection. The extents of HR were anatomical resection in 144 (85.7%) and nonanatomical resection including subsegmentectomy and partial hepatectomy in 24 (14.3%). Laparoscopic HR and concurrent bile duct

on
ati
ific
ISSI
cla
0
Ť
>
10
20
je
t
to
ng
rd
CO
ac
oma a
on
.≘.
arc
ОС
jgi
lar
ho
oma-cl
шŝ
IOU
. <u>.</u>
car
ar (
n
ell
00
pat
Jel
þ
ne
iqu
comk
h c
∕ith
ents witl
nts
tie
ра
38
1(
he
of t
S C
rre
att
fe
cal
. <u>5</u> 0
olo
th
ba
CO
ini
Cli
<u>-</u> -
e
ab
H-

VariableAllClassical type (A)Typical (B)Patient168 (100)86 (51.2)23 (13.7)Age (yr)56.6 \pm 10.756.1 \pm 11.454.0 \pm 7.8Sex, male:female122:4668:1717.7Background liver disease87.8355 (1.6)15 (65.2)HBV infection63.6644.7717.7Background liver disease87.8353 (61.6)15 (65.2)HBV infection63.6644.7714.33Ottor63.6644.7714.43Ottor230.0432.15.429.(33.7)Serum α -FP (ng/mL)2,330.043,756.499.11Serum α -FP (ng/mL)2,330.0437.669.0Median1.2.011.029.(33.7)7.30.4Serum α -FP (ng/mL)29.44.69.411.03.1(3.0)Serum α -FP (ng/mL)29.44.69.411.23.1(3.0)Serum α -FP (ng/mL)29.44.69.411.23.1(3.0)Serum α -FP (ng/mL)29.44.69.411.93.1(3.0)Serum α -FP (ng/mL)29.44.69.411.93.1(3.0)Serum α -FP (ng/mL)29.44.69.411.23.1(3.0)Serum α -FP (ng/mL)29.44.69.411.214.43Innor size (cm)14.48		Subtypes with stem cell features			
Variable All Lassicat type (M) Typical (B) Patient 168 (100) 86 (51.2) 23 (13.7) Age (Y) 56.6 ± 10.7 56.1 ± 11.4 54.0 ± 7.8 Sex, male:female 122:46 68.17 17.7 Background liver disease 98 (58.3) 56 (1.6) 15 (65.2) HBV infection 63.6.1 29 (33.7) 7 (30.4) Dthes 6.3.6.1 29 (33.7) 7 (30.4) Dthes 6.3.6.1 29 (33.7) 7 (30.4) Dthes 8.2 99.1 14.3 7 (30.4) Dthes 8.2 99.1 16.3 10.0 Median 12.2 94.4.69 11.3 27.6 Median 12.5 12.3 66.11.9 3 (13.0) Serum CA 19-9 (ng/mL) 2.94 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Median 12.5 63.4.9 11.0 27.0 Serum CA 19-9 (ng/mL) 2.94 ± 6.6 11.3 ± 7.8 27.3.9 Median 11.5 ± 5.7 12.3 \pm					(e – –
Patient168 (100)86 (51.2)23 (13.7)Age (y1)56.6 \pm 10.756.1 \pm 11.454.0 \pm 7.8Sex, male:female122:4668:1717.7Background liver disease98 (58.3)53 (61.6)15 (65.2)HBV infection6 (3.6)16 (3.6)16 (3.6)15 (65.2)HCV infection6 (3.6)4 (4.7)7 (30.4)Median6 (3.6)15,35,56.494.1 ± 3,396.71,324.4Serum a: FP (ng/mL)2,330.02,37,56.494.1 ± 3,396.71,324.3Median2,30.02,37,56.494.1 ± 3,396.71,324.3 ± 4,567.9Median2,30.02,37,56.494.1 ± 3,396.71,324.3 ± 4,567.9Median12,0011.2,011.027,0Serum CA 19-9 (ng/mL)2,94.4 ± 9,4112 (14.0)3 (13.0)Median12,2312,34.611.9 ± 4,6Median11,5 \pm 5.712.3 ± 6,611.9 \pm 4,6Median11,5 \pm 5.712,34.917 (73.9)Needian13,53,64.917 (73.9)Median3,55,4 (21.9)20 (11.9)Incoresized con14,6 (5.9)11,6 (5.9)Median3,55,4 (32.1)2,9 (33.7)Median3,55,4 (32.1)2,9 (33.7)Median3,55,4 (32.1)2,9 (33.7)Median3,55,4 (32.1)2,9 (33.7)Median5,55,4 (32.1)2,9 (33.7)Median5,55,4 (32.1)2,9 (33.7)Median5,55,		(C) Cholangiolocellular (D) Unclassifiable (E)	Unclassifiable (E)	Б+С+U+E	r-value
Age (yr) 5.6 ± 10.7 5.1 ± 11.4 $5.4.0 \pm 7.8$ Sex, male:female $122:46$ $68:17$ 17.7 Background liver disease $122:46$ $68:17$ 17.7 Background liver disease $8(58.3)$ $53(61.6)$ $15(65.2)$ HCV infection $6(3.6)$ $4(4.7)$ $1(4.3)$ Others $64(38.1)$ $29(33.7)$ $7(30.4)$ Serum α -FP (ng/mL) $4,181.2 \pm 35,936.4$ $994.1 \pm 3,396.7$ $1,324.3 \pm 4,567.9$ Median 3.00 4.00 $2,330.0 \pm 3,756.4$ $994.1 \pm 3,396.7$ $1,324.3 \pm 4,567.9$ Median $2,330.0 \pm 3,756.4$ $994.1 \pm 3,396.7$ $1,324.3 \pm 4,567.9$ Median $2,330.0 \pm 3,756.4$ $994.1 \pm 3,396.7$ $1,324.3 \pm 4,567.9$ Median $2,910.9$ 14.0 $2,70$ Serum CA 19-9 (ng/mL) $2,94 \pm 69.4$ 11.3 ± 80.7 11.3 ± 7.8 Median $29,01.9$ $11.2,01$ 11.0 ± 4.6 Prooperative 12.0 $12.12,3 \pm 6.6$ 11.9 ± 4.6 Prooperative 12.0 12.3 ± 6.6 11.9 ± 4.6 Prooperative $12.65.2$ 3.4 3.0 Median 3.55 3.4 3.0 No exection $159.94.6$ 79.93 14.6 No exection $159.94.6$ $12.42.8$ No exection $11.65.2$ 3.7 No exection $14.65.2$ 3.7 Median 3.55 3.4 No exection $14.66.7$ 79.93 No exection $14.66.7$ 79.93 No exection <td></td> <td>23 (13.7)</td> <td>3 (1.8)</td> <td>82 (48.8)</td> <td></td>		23 (13.7)	3 (1.8)	82 (48.8)	
Sex, male:female122:4668:1717:7Background liver disease98 (38.3)53 (61.6)15 (65.2)HBV infection64 (38.1)29 (33.7)7 (30.4)HCV infection64 (38.1)29 (33.7)7 (30.4)Others64 (38.1)29 (33.7)7 (30.4)Serum a:64 (38.1)29 (33.7)7 (30.4)Median8.2994.1 ± 3,396.71,324.3 ± 4,567.9Median2.30.0 ± 3,756.4994.1 ± 3,396.71,324.3 ± 4,567.9Median11.012.011.2 (4.0)9.0Median11.511.2 (14.0)3 (13.0)Median11.5 ± 5.712.3 ± 6.611.9 ± 4.6Median11.5 ± 5.712.3 ± 6.611.9 ± 4.6Proopendia11.5 ± 5.712.3 ± 6.611.9 ± 4.6Proopendia11.5 ± 5.712.3 ± 6.611.9 ± 4.6Proopendia11.5 ± 5.712.3 ± 4.5 ± 2.94.2 ± 2.8Median11.6 (7.9)7 (14.0)17 (73.9)Romerizel resection14.4 (85.7)7 3 (84.9)17 (73.9)Noterizel resection114 (85.7)7 3 (84.9)17 (73.9)Needian55 (4.2)7 3 (4.0)3 (13.0)Single11.4 (85.7)7 3 (84.9)17 (73.9)Median56 (7.0)7 (4.2)7 (4.7)Median56 (7.0)7 (4.7)9 (6.5)Nutriple7 (4.2)4 (4.7)0 (0)Multiple7 (4.2)8 (40.5)3 (4.0)Multiple7 (4.2) <td>54.0 ± 7.8 51</td> <td>60.6 ± 10.3</td> <td>71.0 ± 10.0</td> <td>57.1 ± 10.0</td> <td>0.571</td>	54.0 ± 7.8 51	60.6 ± 10.3	71.0 ± 10.0	57.1 ± 10.0	0.571
Background liver disease 98 (58.3) 53 (61.6) 15 (65.2) HBV infection 6 (3.6) 4 (4.7) 1 (4.3) Others 6 (3.6) 4 (4.7) 7 (3.3) Others 6 (3.6) 9 (3.7) 7 (3.3) Others 6 (3.8.1) 29 (3.3.7) 7 (3.3.4) Serum α -FP (ng/mL) 4,181.2 ± 35,936.4 116.3 ± 315.4 28,617.7 ± 93,489.9 Median 8.2 99.1 ± 3,396.7 1,324.3 ± 4,567.9 Median 29,0 38.1 ± 80.7 11.3 ± 7.8 Median 29,4 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Median 29,4 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Nedian 12.0 14.4.0 9.0 ICC-RIS (%) 11.4 46.7 7 (3.4) 14.6 Preoperative 20 (11.9) 7 (4.4) 1 (4.3) Iumor size (cm) 4.4 ± 5 2 (4.1) 1 (4.3) Iumor size (cm) 4.4 ± 5 2 (4.1) 1 (4.7) Single 14.4 (6.7) 7 (6.3) 1 (6.5 ± 2) <t< td=""><td>17:7</td><td>16:7</td><td>2:1</td><td>53:29</td><td>0.026</td></t<>	17:7	16:7	2:1	53:29	0.026
HBV infection98 (58.3)53 (61.6)15 (55.2)HCV infection6 (3.6)4 (4.7)1 (4.3)Others6 (3.6)4 (4.7)1 (4.3)Serum ar-FP (ng/mL)4,181.2 ± 35,936.4116.3 ± 315.428,617.7 ± 93,489.9Median6 (3.6)3.756.499.1 ± 3,396.71,324.3 ± 4,567.9Median30.040.027.027.0Serum CA 19-9 (ng/mL)2,930.040.027.0Serum CA 19-9 (ng/mL)29,4 ± 69.438.1 ± 80.711.3 ± 7.8Median12.011.5 ± 5.712.3 ± 6.611.9 ± 4.6Properative20 (11.9)12 (14.0)3 (13.0)Icc-R15 (%)11.5 ± 5.712.3 ± 6.611.9 ± 4.6Properative11.5 ± 5.712.3 ± 6.611.9 ± 4.6Properative11.6 (7.9)7 (4.0)7 (3.2)Borneral resection14.4 (85.7)7 (84.9)17 (73.9)Ro resection14.4 (85.7)7 (84.9)17 (73.9)Ro resection14.4 (67.9)57 (66.3)15 (65.2)S5114 (67.9)57 (66.3)15 (65.2)S6114 (67.9)57 (66.3)15 (65.2)S6114 (67.9)57 (66.3)16 (67.0)S6114 (67.9)57 (66.3)17 (73.9)Ronerscine14 (67.9)57 (66.3)16 (67.0)S6114 (67.9)57 (66.3)17 (73.9)Nucrisce (cm)3.554 (32.1)29 (34.6)S611.912 (40.9)17 (72.9)S657 (66.3) <td></td> <td></td> <td></td> <td></td> <td>0.232^{-1}</td>					0.232^{-1}
HCV infection $6 (3.6)$ $4 (4.7)$ $1 (4.3)$ Others $6 (4 (38.1)$) $2 9 (33.7)$ $7 (30.4)$ Serum α -FP (ng/mL) $4, 181.2 \pm 35, 936.4$ 116.3 ± 315.4 $28, 617.7 \pm 93, 489.9$ Median 8.2 9.2 $5.7.0$ Serum CA 19-9 (ng/mL) $2, 33.0.0 \pm 3, 756.4$ $994.1 \pm 3, 396.7$ $1, 324.3 \pm 4, 567.9$ Median 12.0 11.5 ± 5.7 12.3 ± 6.6 11.3 ± 7.8 Median 12.0 11.5 ± 5.7 12.3 ± 6.6 11.3 ± 7.8 Neoperative $20 (11.9)$ 12.0 14.0 9.0 CG-R15 (%) 11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Preoperative $20 (11.9)$ 12.0 14.0 9.0 Iccreation 11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Preoperative $20 (11.9)$ 12.0 12.0 14.0 Neodian $15.6 (94.6)$ $79 (91.9)$ $11.7 (73.9)$ Resection $114 (85.7)$ $73 (84.9)$ $17 (73.9)$ Neodian $114 (67.9)$ $57 (66.3)$ $12 (65.2)$ S 56 31.7 $23 (41.9)$ $17 (73.9)$ Unnor vize (cm) 3.5 3.4 $3.3.7$ $3.3.7$ Median $114 (67.9)$ $57 (66.3)$ $12 (65.2)$ Single $114 (67.9)$ $57 (66.3)$ $12 (65.2)$ Single $7 (4.2)$ $4.7 7$ $0 (0)$ Single $114 (67.9)$ $57 (66.3)$ $12 (65.2)$ Single $7 (4.2)$ $4.7 7$ $0 (0)$ Single $114 (67$		9 (39.1)	1 (33.3)	45 (54.9)	
Others $64 (38.1)$ $29 (33.7)$ $7 (30.4)$ Serum α -FP (mg/mL) $4,181.2 \pm 35,936.4$ 116.3 ± 315.4 $28,617.7 \pm 93,489.9$ Median 8.2 9.2 57.0 Serum PVKA-II (mAU/mL) $2,330.0 \pm 3,756.4$ $994.1 \pm 3,396.7$ $7(30.4)$ Median 8.2 9.0 2.70 27.0 Serum CA 19-9 (ng/mL) $2,330.0 \pm 3,756.4$ 38.1 ± 80.7 11.3 ± 7.8 Median 12.0 14.0 2.70 27.0 Serum CA 19-9 (ng/mL) 2.94 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Median 12.0 12.0 14.0 $3 (13.0)$ Serum CA 19-9 (ng/mL) 2.94 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Median 11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Prospeative $20 (11.9)$ $12 (14.0)$ $3 (13.0)$ Iconcregional treatment $14.4 (85.7)$ $73 (84.9)$ $17 (73.9)$ Anatomical resection $14.4 (85.7)$ $73 (84.9)$ $17 (73.9)$ Role 80.7 $11.6 (5.9)$ $57 (66.3)$ $12 (46.5)$ Median 3.5 3.4 3.100 Median 3.5 3.4 3.100 Median 3.5 $57 (66.3)$ $12 (46.5)$ Single $7 (4.2)$ 4.4 ± 2.8 4.5 ± 2.9 4.2 ± 2.8 Matomical resection $14.6 (57.9)$ $57 (66.3)$ $12 (65.2)$ Single $7 (4.2)$ 4.4 ± 2.8 4.5 ± 2.9 4.2 ± 2.8 Median $7 (4.2)$ $4.4.7$ 000 Single <td></td> <td>1 (4.3)</td> <td>0 (0)</td> <td>2 (2.4)</td> <td></td>		1 (4.3)	0 (0)	2 (2.4)	
Serum α -FP (ng/mL)4,181.2 ± 35,936.4116.3 ± 315.428,617.7 ± 93,489.9Median8.29.257.057.0Serum PVKA-II (mAU/mL)2,330.0 ± 3,756.4994.1 ± 3,396.71,324.3 ± 4,567.9Median30.040.027.027.0Serum CA 19-9 (ng/mL)2,330.0 ± 3,756.438.1 ± 80.711.3 ± 7.8Median12.011.012.1 ± 4.09.0Neolian11.5 ± 5.712.3 ± 6.611.9 ± 4.6Median11.5 ± 5.712.3 ± 6.611.9 ± 4.6Neoperative20 (11.9)12 (14.0)3 (13.0)Iconegional treatment144 (85.7)73 (84.9)17 (73.9)Anatomical resection144 (85.7)73 (84.9)17 (73.9)Ro resection144 (85.7)73 (84.9)17 (73.9)Nedian3.53.43.13.0Section144 (85.7)73 (84.9)17 (73.9)Nedian3.53.43.13.0Median3.53.43.13.0Section144 (85.7)73 (84.9)17 (73.9)Nedian3.53.43.10.0Median3.53.43.11.4.3Median727 (32.1)29 (33.7)8 (34.8)Neoperative7 (4.2)7 (4.2)4 (4.7)0 (0)Single7 (4.2)4 (4.7)0 (0)Multiple7 (4.2)4 (4.7)0 (0)Vascular invasion8 (40.5)3 (40.5)3 (10.0)Microscopic <t< td=""><td></td><td>13 (56.5)</td><td>2 (66.7)</td><td>35 (42.7)</td><td></td></t<>		13 (56.5)	2 (66.7)	35 (42.7)	
Median8.29.257.0Serum PVKA-II (mAU/mL)2,330.0 ± 3,756.4994.1 ± 3,396.71,324.3 ± 4,567.9Median30.0 30.0 40.0 27.0 Serum CA 19-9 (ng/mL) 29.4 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Median 12.0 14.0 9.0 9.0 CG-R15 (%) 11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Discoregional treatment 14.0 $20.(11.9)$ $12.(14.0)$ $3.(13.0)$ Anatomical resection $144.85.7$ $73.84.9$ $17.73.9$ No resection $159.94.6$ $79.91.9$ $11.773.9$ No resection $144.85.7$ $73.84.9$ $17.73.9$ Median 3.5 3.4 3.0 Single $11.4(67.9)$ $57.(66.3)$ $12.44.3$ Multiple $7.42.3$ $82.95.3$ $23.(100)$ Multiple $7.4.2$ $30.45.3$ $34.43.3$ Numor number $161.95.8$ $82.95.3$ $23.(100)$ Single $161.95.8$ $39.(45.3)$ $11.47.8$ Median $7.4.2$ $39.(45.3)$ $11.47.8$ Multiple $7.4.2$ $39.(45.3)$ $11.47.8$ Ma		16.2 ± 40.8	3.7 ± 2.5	$8,517.2 \pm 51,483.3$	0.153
Serum PIVKA-II (mAU/mL)2,330.0 $\pm 3,756.4$ 994.1 $\pm 3,396.7$ 1,324.3 $\pm 4,567.9$ Median30.040.027.0Serum CA 19-9 (ng/mL)29.4 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Median12.014.09.0CG-R15 (%)11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Preoperative20 (11.9)12 (14.0)3 (13.0)locoregional treatment144 (85.7)73 (84.9)17 (73.9)Anatomical resection144 (85.7)73 (84.9)17 (73.9)R0 resection159 (94.6)73 (91.9)1 (4.3)Nedian3.53.43.0 $\times 55$ 114 (67.9)57 (66.3)15 (65.2) $\times 66$ 114 (67.9)57 (66.3)15 (65.2) $\times 65$ 114 (67.9)57 (66.3)15 (65.2) $\times 65$ 114 (67.9)57 (66.3)15 (65.2) $\times 65$ 114 (67.9)57 (66.3)15 (65.2) $\times 7$ scular invasion3.53.43.0 $\times 100$ number161 (95.8)82 (95.3)23 (100) $\times 100$ number68 (40.5)39 (45.3)11 (47.8) $\times 100$ number18 (10.7)11 (12.8)3 (13.0) $\times 100$ number18 (10.7)11 (12.8)3 (13.0) $\times 1100$ number $68 (40.5)$ 39 (45.3)11 (47.8) $\times 1000$ number $18 (10.7)$ $11 (12.8)$ 3 (13.0) $\times 11000$ number $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ $\times 1000$ number $18 (10.7)$ $9 (5.4)$ $6 (7.0)$ <td< td=""><td>57.0 11.9</td><td>2.0</td><td>3.5</td><td>8.0</td><td></td></td<>	57.0 11.9	2.0	3.5	8.0	
Median 30.0 40.0 27.0 Serum CA 19-9 (ng/mL) 29.4 ± 69.4 38.1 ± 80.7 11.3 ± 7.8 Median 12.0 14.0 9.0 ICG-R15 %) 11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Preoperative $20 (11.9)$ $12.(14.0)$ $3 (13.0)$ locoregional treatment $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ Anatomical resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ RO resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ RO resection $144 (87.9)$ $57 (66.3)$ $12 (4.0)$ Median 3.5 3.4 3.0 S5 $114 (67.9)$ $57 (66.3)$ $12 (4.3)$ Median 3.5 3.4 3.0 Single $16 (7.9)$ $57 (66.3)$ $15 (65.2)$ Single $16 (7.9)$ $57 (66.3)$ $15 (65.2)$ Single $16 (7.9)$ $29 (33.7)$ $8 (34.8)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Macroscopic $68 (40.5)$ $39 (45.3)$ $11 (47.8)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (40.5)$ $3 (41.9)$ $6 (7.0)$ Macroscopic $16 (40.5)$ $3 (45.3)$ $11 (47.8)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (40.5)$ $3 (38.4)$ $10 (43.5)$ <trr< td=""><td>$1,324.3 \pm 4,567.9$ $1,370.$</td><td>$.6 290.3 \pm 1,067.7$</td><td>144.5 ± 176.1</td><td>$1,058.2 \pm 4,177.7$</td><td>0.922</td></trr<>	$1,324.3 \pm 4,567.9$ $1,370.$	$.6 290.3 \pm 1,067.7$	144.5 ± 176.1	$1,058.2 \pm 4,177.7$	0.922
Serum CA 19-9 (ng/mL) $29,4 \pm 69,4$ 38.1 ± 80.7 11.3 ± 7.8 Median12.014.09.0ICG-R15 (%)11.5 \pm 5.712.3 \pm 6.611.9 \pm 4.6Preoperative20 (11.9)12 (14.0)3 (13.0)locoregional treatment144 (85.7)73 (84.9)17 (73.9)Anatomical resection144 (85.7)73 (84.9)17 (73.9)Ro resection144 (85.7)73 (84.9)17 (73.9)Natomical resection144 (85.7)73 (84.9)17 (73.9)Ro resection144 (85.7)73 (84.9)17 (73.9)Ro resection144 (85.7)73 (84.9)17 (73.9)Ro resection144 (85.7)73 (84.9)17 (73.9)Ro resection144 (67.9)57 (66.3)15 (65.2)Single114 (67.9)57 (66.3)15 (65.2)Single114 (67.9)57 (66.3)15 (65.2)Single161 (95.8)82 (95.3)23 (100)Multiple7 (4.2)4 (4.7)0 (0)Macroscopic68 (40.5)39 (45.3)11 (47.8)Macroscopic18 (10.7)11 (12.8)3 (13.0)Upwith hode metastasis9 (5.4)6 (7.0)0 (0)B25 (14.9)9 (10.5)4 (17.4)II42.4)2 (7.0)0 (0)B25 (14.9)9 (10.5)1 (4.7)III4 (2.4)2 (2.3)1 (4.3.5)III4 (2.4)2 (7.0)0 (0)B2 (4.9)3 (3 (4.9)1 (4.7)III4 (2.		24.0	152.0	27.0	
Median12.014.09.0ICG-R15 %11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Preoperative20 (11.9)12 (14.0)3 (13.0)locoregional treatment20 (11.9)12 (14.0)3 (13.0)Iocoregional treatment144 (85.7)73 (84.9)17 (73.9)Anatomical resection144 (85.7)73 (84.9)17 (73.9)R0 resection144 (85.7)73 (84.9)17 (73.9)R0 resection144 (85.7)73 (84.9)17 (73.9)R0 resection144 (67.9)5.53.43.05554 (32.1)29 (33.7)8 (34.8)114 (67.9)57 (66.3)15 (65.2)5554 (32.1)29 (33.7)8 (34.8)114 (67.9)7 (4.2)4 (4.7)0 (0)%7 (4.2)82 (95.3)23 (100)Multiple7 (4.2)4 (4.7)0 (0)Multiple7 (4.2)4 (4.7)0 (0)Macroscopic18 (10.7)11 (12.8)3 (13.0)Macroscopic9 (5.4)6 (7.0)0 (0)B25 (14.9)3 (6.9)3 (38.4)10 (43.5)III62 (36.9)3 (38.4)10 (43.5)III9 (5.4)6 (7.0)0 (0)119 (5.4)6 (7.0)0 (0)119 (5.4)6 (7.0)0 (0)119 (5.4)6 (7.0)0 (0)119 (5.4)6 (7.0)0 (0)119 (5.4)6 (7.0)0 (0)119 (5.4)6 (7.0)0	11.3 ± 7.8 35.	9.4 ± 7.2	15.5 ± 15.7	21.2 ± 56.3	0.201
ICG-R15 (%) 11.5 ± 5.7 12.3 ± 6.6 11.9 ± 4.6 Preoperative $20 (11.9)$ $12 (14.0)$ $3 (13.0)$ Iocoregional treatment $20 (11.9)$ $12 (14.0)$ $3 (13.0)$ Anatomical resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ Anatomical resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ Ro resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ Ro resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ Ro resection $114 (67.9)$ $55 (65.3)$ $17 (73.9)$ Nedian 3.5 3.4 3.0 3.0 55 $54 (32.1)$ $29 (33.7)$ $8 (34.8)$ 55 $57 (66.3)$ $15 (65.2)$ 3.0 55 $57 (66.3)$ $15 (65.2)$ 3.0 55 $57 (66.3)$ $23 (100)$ $7 (4.2)$ $4 (4.7)$ $0 (0)$ $8 (40.5)$ $39 (45.3)$ $23 (100)$ $Multiple$ $7 (4.2)$ $4 (4.7)$ $0 (0)$ $Multiple$ $7 (4.2)$ $4 (4.7)$ $0 (0)$ $Multiple$ $7 (4.2)$ $39 (45.3)$ $3 (13.0)$ $Multiple$ $7 (4.2)$ $39 (45.3)$ $3 (13.0)$ $Multiple$ $7 (4.2)$ $3 (41.9)$ $8 (34.8)$ $Multiple$ $7 (4.2)$ $3 (4.19)$ $8 (34.8)$ $Multiple$ $10 (70)$ $9 (45.3)$ $11 (47.8)$ $Multiple$ $16 (7.0)$ $9 (40.5)$ $3 (41.9)$ $8 (34.8)$ $Macroscopic18 (40.5)3 (41.9)8 (34.8)$	9.0	7.0	14.0	0.0	
Preoperative $20 (11.9)$ $12 (14.0)$ $3 (13.0)$ locoregional treatment $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ Anatomical resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ R0 resection $159 (94.6)$ $79 (91.9)$ $17 (73.9)$ R0 resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ R0 resection $159 (94.6)$ $79 (91.9)$ $17 (73.9)$ R0 resection $144 (85.2)$ 3.4 3.0 R0 resection 3.5 3.4 3.0 R0 resection $114 (67.9)$ $57 (66.3)$ 4.2 ± 2.8 Median 3.5 $54 (32.1)$ $29 (33.7)$ $8 (34.8)$ Single $114 (67.9)$ $57 (66.3)$ $15 (65.2)$ Single $161 (95.8)$ $82 (95.3)$ $15 (65.2)$ Single $161 (95.8)$ $82 (95.3)$ $23 (100)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Witiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Mitrobe metastasis $9 (5.4)$ $6 (7.0)$ $0 (0)$ Rth AJCC tumor stage $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Mitroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Mathible $25 (14.9)$ $9 (10.5)$ $4 (17.4)$ Mathible </td <td></td> <td>9.3 ± 4.4</td> <td>14.0 ± 2.3</td> <td>10.9 ± 4.7</td> <td>0.143</td>		9.3 ± 4.4	14.0 ± 2.3	10.9 ± 4.7	0.143
Iocoregional treatmentAnatomical resection $144 (85.7)$ $73 (84.9)$ $17 (73.9)$ R0 resection $159 (94.6)$ $79 (91.9)$ $11 (4.3)$ R0 resection $159 (94.6)$ $79 (91.9)$ $1 (4.3)$ R0 resection 3.5 3.4 3.0 $80 \operatorname{resection}$ 3.5 3.4 3.0 $55 \operatorname{cb}$ $57 (66.3)$ 4.2 ± 2.8 $80 \operatorname{cb}$ $57 (66.3)$ $15 (65.2)$ $55 \operatorname{cb}$ $114 (67.9)$ $57 (66.3)$ $15 (65.2)$ $55 \operatorname{cb}$ $114 (67.9)$ $57 (66.3)$ $15 (65.2)$ $57 \operatorname{cb}$ $57 (26.3)$ $15 (65.2)$ 30 $57 \operatorname{cb}$ $7 (3.2, 1)$ $29 (33.7)$ $8 (34.8)$ Immor number $7 (4.2)$ $4 (4.7)$ $0 (0)$ Single $161 (95.8)$ $82 (95.3)$ $23 (100)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Macroscopic $18 (40.5)$ $3 (41.9)$ $8 (34.8)$ Id $25 (14.9)$ $9 (5.4)$ $6 (7.0)$ $0 (0)$ Macroscopic $11 (12.8)$ $3 (13.0)$ $1 (4.3.5)$ II $10 \times 33 (38.4)$ $10 (43.5)$ $1 (4.3.5)$ III $4 (2.4)$ $2 (2.3)$ $1 (4.3.5)$ III $4 (2.4)$ $2 (2.3)$ $1 (4.3.5)$ III $6 (7.0)$ $0 (0)$ $0 (0)$ <td></td> <td>2 (8.7)</td> <td>0 (0)</td> <td>8 (9.8)</td> <td>0.402</td>		2 (8.7)	0 (0)	8 (9.8)	0.402
Anatomical resection144 (85.7) $73 (84.9)$ $17 (73.9)$ R0 resection159 (94.6) $79 (91.9)$ $17 (73.9)$ R0 resection159 (94.6) $79 (91.9)$ $1 (4.3)$ Rumor size (cm) 3.5 3.4 3.0 55 $66.3)$ $14 (67.9)$ $57 (66.3)$ $15 (65.2)$ 55 $54 (32.1)$ $29 (33.7)$ $8 (34.8)$ Rumor number $114 (67.9)$ $57 (66.3)$ $15 (65.2)$ 55 $54 (32.1)$ $29 (33.7)$ $8 (34.8)$ Single $161 (95.8)$ $82 (95.3)$ $15 (65.2)$ Single $161 (95.8)$ $82 (95.3)$ $23 (100)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Wultiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Macroscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Rith AJCC tumor stage $9 (5.4)$ $6 (7.0)$ $0 (0)$ Rith AJCC tumor stage $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Rith AJCC tumor stage $9 (5.4)$ $6 (7.0)$ $0 (0)$ III $62 (36.9)$ $33 (38.4)$ $10 (43.5)$ IIIA $4 (2.4)$ $2 (2.3)$ $1 (4.3.5)$ IIIA $9 (5.4)$ $6 (7.0)$ $0 (0)$					
R0 resection159 (94.6)79 (91.9)1 (4.3)Tumor size (cm) 4.4 ± 2.8 7.5 ± 2.9 $1.4.3 = 3.0$ Median 3.5 3.4 3.0 55 57 (66.3) 15 (55.2) 55 57 (36.3) 15 (55.2) 55 54 (32.1) 29 (33.7) 8 (34.8)Tumor number 161 (95.8) 82 (95.3) 15 (65.2)Single 161 (95.8) 82 (95.3) 23 (100)Multiple 7 (4.2) $4(4.7)$ 0 (0)Waccuscopic 68 (40.5) 39 (45.3) 11 (47.8)Microscopic 68 (40.5) 39 (45.3) 11 (47.8)Microscopic 68 (40.5) 39 (45.3) 11 (47.8)Microscopic 18 (10.7) 11 (12.8) 3 (13.0)Upmph node metastasis 9 (5.4) 6 (7.0) 0 (0)III 62 (36.9) 33 (38.4) 10 (43.5)III 62 (36.9) 33 (38.4) 10 (43.5)IIIA 4 (2.4) 2 (2.3) 1 (4.3.5)IIIA 9 (5.4) 6 (7.0) 0 (0)		22 (95.7)	2 (66.7)	71 (86.6)	0.753
Tumor size (cm) 4.4 ± 2.8 4.5 ± 2.9 4.2 ± 2.8 Median 3.5 3.4 3.0 55 ≤ 5 $114 (67.9)$ $57 (66.3)$ $15 (65.2)$ >5 ≤ 3.11 $29 (33.7)$ $8 (34.8)$ Tumor number $161 (95.8)$ $82 (95.3)$ $23 (100)$ Single $161 (95.8)$ $82 (95.3)$ $23 (100)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Vascular invasion $82 (95.3)$ $23 (100)$ Multiple $7 (4.2)$ $4 (4.7)$ $0 (0)$ Vascular invasion $82 (95.3)$ $23 (100)$ Microscopic $18 (10.7)$ $11 (12.8)$ $31 (3.0)$ Vascular invasion $8 (40.5)$ $39 (45.3)$ $11 (47.8)$ Microscopic $18 (10.7)$ $11 (12.8)$ $3 (13.0)$ Lymph node metastasis $9 (5.4)$ $6 (7.0)$ $0 (0)$ II $62 (36.9)$ $33 (38.4)$ $10 (43.5)$ III $4 (2.4)$ $2 (2.3)$ $1 (4.3)$ III $9 (5.4)$ $6 (7.0)$ $0 (0)$		23 (100)	3 (100)	80 (97.6)	0.172
Median 3.5 3.4 3.0 ≤ 5 ≤ 5 114 (67.9) 57 (66.3) 15 (55.2) >5 54 (32.1) 29 (33.7) 8 (34.8)Tumor number 161 (95.8) 82 (95.3) 23 (100)Single 161 (95.8) 82 (95.3) 23 (100)Multiple 7 (4.2) 4 (4.7) 0 (0)Warston 82 (95.3) 23 (100)Multiple 7 (4.2) 4 (4.7) 0 (0)Vascular invasion 82 (95.3) 23 (100)Microscopic 68 (40.5) 39 (45.3) 11 (47.8)Microscopic 18 (10.7) 11 (12.8) 3 (13.0)Upmph node metastasis 9 (5.4) 6 (7.0) 0 (0)I 8 (40.5) 36 (41.9) 8 (41.9) 8 (44.8)I 10.7 11 (12.8) 31 (34.8)I 10.7 11 (12.8) 3 (13.0)I 10.7 11 (12.8) 3 (13.0)I 10.7 11 (12.8) 3 (13.0)I 10.7 33 (38.4) 10 (41.5)I 11 22 (14.9) 36 (41.9) 8 (44.5)I 11 6 (7.0) 9 (10.5) 10 (43.5)I 11 2 (23.3) 1 (12.3) 1 (17.4)I 11 2 (23.3) 1 (14.3) 1 (14.3)III 9 (5.4) 6 (7.0) 0 (0)		4.3 ± 2.0	8.1 ± 7.8	4.3 ± 2.6	0.713
	3.0 3.6	4.1	5.0	3.5	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		15 (65.2)	2 (66.7)	57 (69.5)	
Tumor numberTumor numberSingle161 (95.8)82 (95.3)23 (100)Multiple7 (4.2)4 (4.7)0 (0)Vascular invasion68 (40.5)39 (45.3)11 (47.8)Microscopic18 (10.7)11 (12.8)3 (13.0)Macroscopic9 (5.4)6 (7.0)0 (0)Macroscopic18 (10.7)11 (12.8)3 (13.0)Macroscopic18 (10.7)11 (12.8)3 (13.0)Macroscopic9 (5.4)6 (7.0)0 (0)B25 (14.9)9 (10.5)4 (17.4)I62 (36.9)33 (8.4)10 (43.5)IIIA4 (2.4)2 (2.3)1 (4.3)IIIB9 (5.4)6 (7.0)0 (0)		8 (34.8)	1 (33.3)	25 (30.5)	
Single161 (95.8)82 (95.3)23 (100)Multiple7 (4.2)4 (4.7)0 (0)Vascular invasion88 (40.5)39 (45.3)11 (47.8)Microscopic68 (40.5)39 (45.3)11 (47.8)Macroscopic18 (10.7)11 (12.8)3 (13.0)Nacroscopic9 (5.4)6 (7.0)0 (0)Upmph node metastasis9 (5.4)6 (7.0)0 (0)Bh AJCC tumor stage68 (40.5)36 (41.9)8 (34.8)I6 (7.0)33 (38.4)10 (43.5)II6 (7.0)9 (5.4)6 (7.0)0 (0)IIIA9 (5.4)6 (7.0)0 (0)					0.534
$ \begin{array}{llllllllllllllllllllllllllllllllllll$		23 (100)	3 (100)	79 (96.3)	
Vascular invasion 68 (40.5) 39 (45.3) 11 (47.8) Microscopic 68 (40.7) 11 (12.8) 3 (13.0) Macroscopic 18 (10.7) 11 (12.8) 3 (13.0) Macroscopic 18 (10.7) 11 (12.8) 3 (13.0) Itymph node metastasis 9 (5.4) 6 (7.0) 0 (0) 8th AJCC tumor stage 68 (40.5) 36 (41.9) 8 (34.8) IA 25 (14.9) 9 (10.5) 4 (17.4) IB 25 (14.9) 33 (38.4) 10 (43.5) III 62 (36.9) 33 (38.4) 10 (43.5) IIIA 9 (5.4) 6 (7.0) 0 (0)	0 (0) 3 (9.1)	0 (0)	0 (0)	3 (3.7)	
$ \begin{array}{ccccc} \mbox{Microscopic} & 68 (40.5) & 39 (45.3) & 11 (47.8) \\ \mbox{Macroscopic} & 18 (10.7) & 11 (12.8) & 3 (13.0) \\ \mbox{Lymph node metastasis} & 9 (5.4) & 6 (7.0) & 0 (0) \\ \mbox{Rh AJCC tumor stage} & & \\ Rh AJCC $					
$ \begin{array}{c ccccc} \mbox{Macroscopic} & 18 (10.7) & 11 (12.8) & 3 (13.0) \\ \mbox{Lymph node metastasis} & 9 (5.4) & 6 (7.0) & 0 (0) \\ \mbox{Bth AlCC tumor stage} & 68 (40.5) & 36 (41.9) & 8 (34.8) \\ \mbox{IA} & 68 (40.5) & 36 (41.9) & 8 (34.8) \\ \mbox{IB} & 25 (14.9) & 9 (10.5) & 4 (17.4) \\ \mbox{II B} & 25 (14.9) & 33 (38.4) & 10 (43.5) \\ \mbox{II IA} & 4 (2.4) & 2 (2.3) & 1 (4.3) \\ \mbox{II IB} & 9 (5.4) & 6 (7.0) & 0 (0) \\ \end{array} $		3 (13.0)	2 (66.7)	29 (35.4)	0.192
Lymph node metastasis 9 (5.4) 6 (7.0) 0 (0) 8th AJCC tumor stage 68 (40.5) 36 (41.9) 8 (34.8) IA 68 (40.5) 36 (41.9) 8 (34.8) IB 25 (14.9) 9 (10.5) 4 (17.4) II 62 (36.9) 33 (38.4) 10 (43.5) IIIA 4 (2.4) 2 (2.3) 1 (4.3) IIIB 9 (5.4) 6 (7.0) 0 (0)	3 (13.0)	2 (8.7)	0 (0)	7 (8.5)	0.373
8th AJCC tumor stage $88 (40.5)$ $36 (41.9)$ $8 (34.8)$ IA $68 (40.5)$ $36 (41.9)$ $8 (34.8)$ IB $25 (14.9)$ $9 (10.5)$ $4 (17.4)$ II $62 (36.9)$ $33 (38.4)$ $10 (43.5)$ IIIA $4 (2.4)$ $2 (2.3)$ $1 (4.3)$ IIIB $9 (5.4)$ $6 (7.0)$ $0 (0)$		1 (4.3)	0 (0)	3 (3.7)	0.272
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					0.421°
IB $25(14.9)$ $9(10.5)$ $4(17.4)$ II $62(36.9)$ $33(38.4)$ $10(43.5)$ IIIA $4(2.4)$ $2(2.3)$ $1(4.3)$ IIIB $9(5.4)$ $6(7.0)$ $0(0)$	8 (34.8) 1	12 (52.2)	1 (33.3)	32 (39.0)	
II $62 (36.9)$ $33 (38.4)$ $10 (43.5)$ IIIA $4 (2.4)$ $2 (2.3)$ $1 (4.3)$ IIIB $9 (5.4)$ $6 (7.0)$ $0 (0)$	4 (17.4)	7 (30.4)	0 (0)	16 (19.5)	
IIIA 4 (2.4) 2 (2.3) 1 (4.3) IIIB 9 (5.4) 6 (7.0) 0 (0)		3 (13.0)	1 (33.3)	29 (35.4)	
IIIB 9 (5.4) 6 (7.0) 0 (0)		0 (0)	1 (33.3)	2 (2.4)	
		1 (4.3)	0 (0)	3 (3.7)	
Anto il vino tedmini no noiteiven niednets 4 neem 1%) tedmini se netnesen ere sellev	ion or number only if otherwise specified				
values are presented as number (%), mean ± standard deviation, or number only it otnerwise specified. PIVKA-II proteins induced by vitamin K antagonist or absence-II: ICG-R15 indocvanine green retention test at 15 minutes: MELD model for end-stage liver disease: AICC American	ion, or number only it otherwise specifiea. ce-ll: ICG-R15_indocvanine_green_retention	est at 15 minutes: MFLD, m	odel for end-stage	liver disease: AICC	American
JINNATILY DIVIDENDI INDUCED by VIGNING ANGROUPS OF ADSCREETLY INCOMING TO CAMPAGE			indei ini eind-stage		
^{a)} A vs (B + C + D + F) ^{b)} Viral henatitis vs others ^{c)} Stage I vs. other advanced stages.	other advanced stages				

Annals of Surgical Treatment and Research 2021;100(5):260-269

ASTR

resection were performed in 17 (10.1%) and 4 (2.4%), respectively (Table 2).

The pathological findings of these patients are summarized in Table 1. Mean tumor diameter was 4.4 ± 2.8 cm, and 161 patients (95.8%) had solitary tumors. Histologically, 86 patients (51.2%) had classical-type cHCC-CCs, whereas 82 (48.8%) had tumors with SC features, including 23 (13.7%) with typical subtype, 33 (19.6%) with intermediate-cell subtype, 23 (13.7%) with cholangiolocellular subtype, and 3 (1.8%) with unclassifiable type. Except for age, there were no statistically significant differences in clinical and pathological features in patients assorted by the 2010 WHO classification (Table 1).

Postresection prognosis

None of these 168 patients died of perioperative complications.

Table 2. Extents of hepatic resection

Types of resection	Data	
Anatomical resection	144 (85.7)	
Right hepatectomy ± caudate resection	26	
Left hepatectomy \pm caudate resection	29	
Right anterior sectionectomy	27	
Right posterior sectionectomy	26	
Central bisectionectomy	12	
Left lateral sectionectomy	16	
Left medial sectionectomy	3	
Caudate lobectomy	2	
Right trisectionectomy	3	
Nonanatomical resection, partial hepatectomy ^{a)}	24 (14.3)	
Concurrent bile duct resection	4 (2.4)	
Laparoscopic resection	17 (10.1)	

Values are presented as number (%) or number only.

^{a)}Including subsegmentectomy and nonanatomical partial hepatectomy.

В Α 1.0 1.0 0.8 0.8 Proportion of recurrence Proportion of survival 0.6 0.6 0.4 0.4 0.2 0.2 0 0 1 2 3 4 5 6 7 8 2 3 4 5 6 8 1 Postoperative period (yr) Postoperative period (yr)

During a mean follow-up period of 43.8 ± 24.8 months (range, 3–95 months), 90 patients (53.6%) had recurrent tumors.

The preferred initial treatments for these recurrent lesions were TACE (n = 31), radiofrequency ablation (n = 10), and systemic chemotherapy (n = 10) for intrahepatic recurrence; and systemic chemotherapy for intra- and extrahepatic recurrence (n = 7), pulmonary metastasis (n = 5), and intraperitoneal extrahepatic metastasis (n = 7). No specific recurrence treatment was provided to 13 patients because of poor general condition

 Table 3. Initial treatments for the first recurrence in 90 patients with postresection tumor recurrence

Site of first recurrence	Data
Intrahepatic recurrence	62 (68.9)
TACE	31
RFA	10
Repeat resection	5
Liver transplantation	1
Chemotherapy ^{a)}	10
No specific treatment	5
Intra- and extrahepatic recurrence ^{b)}	12 (13.3)
TACE	1
Chemotherapy ^{a)}	7
No specific treatment	4
Pulmonary metastasis	5 (5.6)
Chemotherapy	5
Intraperitoneal extrahepatic metastasis	11 (12.2)
Chemotherapy ^{a)}	7
No specific treatment	4

Values are presented as number (%) or number only.

TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation.

^{ai}Chemotherapy regimens included gemcitabine, 5-fluorouracil, sorafenib, and other agents. ^{bi}Including lung and intraperitoneal metastases.

Fig. 1. Kaplan-Meier analysis of (A) tumor recurrence and (B) overall survival of all 168 patients with combined hepatocellular carcinoma-cholangiocarcinoma.

ASTR

and rapid tumor progression (Table 3).

The cumulative 1-, 3-, and 5-year tumor recurrence rates in these patients were 31.9%, 49.6%, and 58.1%, respectively, whereas their 1-, 3-, and 5-year overall patient survival rates were 91.0%, 70.2%, and 60.3%, respectively (Fig. 1).

According to the 8th AJCC staging system, 68 patients (40.5%) had stage IA, 25 (14.9%) had stage IB, 62 (36.9%) had stage II, 4 (2.4%) had stage IIIA, and 9 (5.4%) had stage IIIB tumors. Tumor recurrence and patient survival rates showed definite prognostic contrasts according to 8th AJCC tumor stages (all P < 0.001) (Fig. 2).

Risk factor analysis for postresection prognosis

Univariate analyses revealed that significant risk factors for both tumor recurrence and overall patient survival included tumor size of >5 cm, microscopic and macroscopic vascular invasion, lymph node metastasis, 8th AJCC tumor stage, and 2010 WHO histologic classification (Table 4). Because tumor size of >5 cm, microscopic and macroscopic vascular invasion, and lymph node metastasis are essential components of the 8th AJCC tumor staging system, these risk factors can be simplified as the 8th AJCC tumor stage and 2010 WHO histologic classification. Multivariate analysis showed that these 2 factors were also independent prognostic factors for tumor recurrence and overall patient survival (Table 5).

Prognostic analysis according to the 2010 World Health Organization classification

To avoid the confounding effects from less frequent findings, patients with 8th AJCC stage III tumors and unclassifiable subtype, and those who underwent R1 resection, were excluded. Analysis of the 146 patients with 8th AJCC stages I and II cHCC-CCs showed that tumor recurrence rate was significantly higher (P = 0.003) and overall survival significantly lower (P = 0.019) in patients with classical-type cHCC-CCs than in those with tumors with SC feature subtypes (Fig. 3). Furthermore, analysis of the 74 patients with 8th AJCC stages I and II cHCC-CCs with SC features showed no significant differences among these 3




Fig. 2. Kaplan-Meier analysis of (A) tumor recurrence and (B) overall survival of patients classified according to the 8th edition of American Joint Committee on Cancer tumor staging system.

Minjae Kim, et al: Prognosis of combined hepatocellular carcinoma-cholangiocarcinoma

Variable	No. of patients	Tumor recurrence		Overall patient survival		
variable	No. of patients	5-yr recurrence rate (%)	P-value	5-yr survival rate (%)	P-value	
Sex			0.412		0.613	
Male	122	60.2		59.2		
Female	46	51.2		63.5		
Background liver disease			0.383		0.332	
Viral hepatitis	104	56.0		66.2		
Others	64	59.3		50.0		
Serum α -FP (ng/mL)			0.641		0.314	
≤7	69	64.8		62.4		
>7	86	56.6		56.6		
Serum PIVKA-II (mAU/mL)			0.153		0.341	
≤40	91	59.0		63.4		
>40	55	67.6		55.3		
Serum CA 19-9 (ng/mL)		0.10	0.202	00.0	0.095	
≤37	100	62.9	0.202	55.8	0.055	
>37	11	72.7		36.4		
Anatomical resection		, 2.,	0.714	50.1	0.463	
Yes	144	57.7	0.7 1 1	58.2	0.105	
No	24	67.4		72.4		
Surgical curability	24	07.4	0.162	72.7	0.182	
R0 resection	159	57.7	0.102	61.6	0.102	
R1 resection	9	66.7		38.9		
Tumor size (cm)	5	00.7	0.006	50.5	< 0.001	
≤5	114	51.4	0.000	70.6	<0.001	
>5	54	71.6		37.6		
Tumor number	54	71.0	0.133	57.0	0.133	
Single	161	57.6	0.155	61.3	0.155	
Multiple	7	71.4		38.1		
•	/	/1.4	-0.001	50.1	<0.001	
Microscopic vascular invasion Absent	100	49.8	< 0.001	73.7	< 0.001	
Present	68	71.0	0.010	39.3	0.001	
Macroscopic vascular invasion	150		0.012		< 0.001	
Absent	150	56.1		65.0		
Present	18	76.3	0.001	15.2	0.010	
Lymph node metastasis	150	56.0	0.001	(2.2	0.012	
Absent	159	56.3		62.2		
Present	9	100	.0.001	27.8	.0.001	
8th AJCC tumor stage	63	40 7	< 0.001	75 5	< 0.001	
	93	49.7		75.5		
II and III	75	69.3	0.000	40.7		
2010 WHO classification	<i>c</i> -		0.003		0.010	
Classical type	86	68.1		51.8		
Subtypes with stem cell features	82	47.9		68.9		

Table 4. Univariate analyses of factors associated with tumor recurrence and patient survival

PIVKA-II, proteins induced by vitamin K antagonist or absence-II; 8th AJCC, 8th edition of American Joint Committee on Cancer; WHO, World Health Organization.

histologic subtypes in tumor recurrence rate (P = 0.331) and patient survival (P = 0.972) (Fig. 4).

DISCUSSION

cHCC-CCs are rare tumors, comprising approximately 2.6% of

primary liver malignancies in the present study. This incidence was lower than the 5.8% reported in our previous study [4] but was generally consistent with rates ranging from 0.8% to 14.3% of primary liver malignancies in other patient populations [10-12]. A population-level analysis in the United States found that between 1988 and 2009, 52,825 patients had HCC, 7,181 had



Table 5. Multivariate analyses of factors associated with tumor recurrence and patient surviva	Table 5. Multivariate anal	yses of factors associated	with tumor recurrence an	d patient survival
---	----------------------------	----------------------------	--------------------------	--------------------

Variable	Tumor recurrence			Overall patient survival		
variable	HR	95% CI	P-value	HR	95% CI	P-value
8th AJCC tumor stage			< 0.001			< 0.001
1	1					
II and III	2.23	1.46-3.41		3.61	2.13-6.13	
2010 WHO classification			0.002			0.003
Subtypes with stem cell features	1			1		
Classical type	1.97	1.29-3.02		2.17	1.29–3.64	

HR, hazard ratio; CI, confidence interval; 8th AJCC, 8th edition of American Joint Committee on Cancer; WHO, World Health Organization.




Fig. 3. Kaplan-Meier analysis of tumor recurrence and overall survival in patients who underwent R0 resection for classicaltype combined hepatocellular carcinoma and cholangiocarcinoma and subtypes with stem cell features according to the 2010 World Health Organization classification. (A) Tumor stages I and II, (B) tumor stage I, and (C) tumor stage II of the 8th edition of American Joint Committee on Cancer.

ICC, and 465 had cHCC-CC, making the proportion of those with cHCC-CC 0.8% [13].

Advances in molecular biology have led to the development of the cancer SC theory of solid neoplasms. Primary liver cancers, including HCC, ICC, and cHCC-CC, are thought to originate from HPCs. HPCs are liver-specific adult SCs that are activated when mature hepatocytes and/or cholangiocytes are damaged. Advances in HPC research have provided insight into the development of cHCC-CCs [14-16]. These tumors are to derive from bipotent HPCs, which are intermediate SCs capable of undergoing bidirectional differentiation into hepatocytes or bile duct epithelial cells [17-20]. Microdissection of cHCC-CCs and DNA extraction showed that both the hepatocellular and cholangiocellular components of these tumors share identical allelic losses, suggesting their monoclonal origin [21]. Gene expression profiling, however, showed that biliary committed cells were precursors of cholangiolocellular type, and biphenotypic progenitor-like cells were precursors of the




Fig. 4. Kaplan-Meier analysis tumor recurrence and overall survival in patients who underwent R0 resection for the 3 subtypes of combined hepatocellular carcinoma and cholangiocarcinoma with stem cell features, as determined by the 2010 World Health Organization classification. (A) Tumor stages I and II, (B) tumor stage I, and (C) tumor stage II of the 8th edition of American Joint Committee on Cancer.

classical type and other SC subtypes of cHCC-CCs, suggesting that these tumors may derive from more than one cell type [22].

The 2010 WHO classification divides cHCC-CCs into 2 types, the classical type and subtypes with SC features [3]. The classical type, which contains areas typical of both HCC and ICC, was observed in 51.2% of our patients. These tumors are thought to develop from independent and separate HCCs and ICCs. HCCs develop first and transform into ICC or vice versa. Alternatively, malignant changes may occur first in HPCs, followed by their differentiation into HCC and ICC to variable degrees.

Although cHCC-CCs with SC features were initially reported to be rare [6], they are actually relatively common, with 48.8% of patients in the present study having this tumor type, including 13.7% with the typical subtype. The intermediate-cell subtype, observed in 19.6% of patients, corresponds to liver carcinoma of the intermediate (hepatocyte-cholangiocyte) phenotype [23]. Cholangiolocellular carcinoma was classified as a subtype of ICC in previous WHO classifications, but, in 2010, it was classified as a cholangiolocellular subtype of cHCC-CC with SC features [24]. Although considered a rare malignant liver tumor, 13.7% of the patients in this study had cholangiolocellular carcinoma [24]. In addition, tumors in 1.8% of our patients could not be classified. These findings indicate that the classification of various subtypes of cHCC-CC patients with SC features is still challenging and requires further validation [6].

At the time the 2010 WHO classification was introduced, prognosis of patients was thought to be worse in patients with SC features than in patients with HCC. However, the prognosis of patients with cHCC-CC and SC features had not been determined, as findings were based on conflicting evidence from studies that included relatively few patients [3]. Several small-volume studies have assessed the prognosis of patients with cHCC-CC classified according to the 2010 WHO guidelines. Although a Japanese study reported that patients with subtypes with SC features had poorer survival outcomes than patients with classical type [5], another found no significant differences in survival outcomes between these patients with classical type and subtypes with SC features [6]. Moreover, retrospective classification of 63 cHCC-CC specimens, all of which were reported to contain all 3 SC subtypes in various degrees and combinations, according to the 2010 WHO classification, found that 4 (6.3%) could be classified as the classical type, and 3 (4.8%), 28 (44.4%) and 27 (42.9%) as having typical, intermediatecell and cholangiolocellular subtypes of cHCC-CCs with SC features, respectively [7]. The proportions of these subtypes varied widely in these 3 Japanese studies. Our previous study of postresection prognosis in 100 patients with cHCC-CC found that the presence of SC features was closely associated with favorable tumor biology [4]. However, we found that histologic type according to the 2010 WHO classification was not an independent prognostic factor in that study, primarily because of the relatively small sample number and the short follow-up period.

The results of present study clearly demonstrated that the histological types of cHCC-CC according to the 2010 WHO classification and tumor staging were independently prognostic of tumor recurrence and overall patient survival. Patients having subtypes with SC features showed better prognosis than those with classical-type cHCC-CC, but there were no differences among patients with the 3 subtypes with SC features. To our knowledge, the present study is the largest cohort study of patients who were prospectively diagnosed with cHCC-CC according to the 2010 WHO classification. Our previous comparison of prognosis in patients with cHCC-CC and a propensity score-matched group of patients with ICC showed that postresection tumor recurrence and patient survival were similar in patients with classical-type cHCC-CC and ICC [4], whereas survival outcomes were improved in patients having cHCC-CC subtypes with SC features [5,25]. These results suggested that classical-type cHCC-CC and ICC may share similarly aggressive tumor biology, but that subtypes with SC features may have less aggressive tumor biology.

The recurrence rate of cHCC-CC after HR was high. Methods used to treat recurrent lesions include liver-directed therapy, such as TACE and systemic chemotherapy. TACE is frequently used to treat recurrent cHCC-CC lesions, but its therapeutic effect is unclear because of the histological heterogeneity of cHCC-CCs, with these tumors being more fibrotic and less vascular than HCCs [26]. Studies of the efficacy of TACE in patients with primary unresectable and recurrent cHCC-CCs in our institution found that treatment response and prognosis were highly related to tumor vascularity [27,28]. The role of systemic chemotherapy for unresectable and recurrent cHCC-CCs remains unclear, although it has been associated with unfavorable outcomes. For example, a multicenter study involving 36 patients evaluating several first-line treatments, including gemcitabine/cisplatin, fluorouracil/cisplatin, and sorafenib, showed that overall survival was poorer in patients who received sorafenib monotherapy than in those treated with platinum-containing regimens [29].

This study had several limitations, including its retrospective design, and inclusion of patients at a single center in a HBVendemic area. Multi-regional, multicenter collective studies are needed to validate the prognostic influence of cHCC-CC subtypes with SC features.

In conclusion, cHCC-CC is a neoplasm with wide histologic diversity, indicating a strong association with HPCs. Patients classified as having cHCC-CC subtypes with SC features have better postresection outcomes than those classified as having classical-type cHCC-CC, suggesting a close association between the postresection outcomes and the histological types according to the 2010 WHO classification.

ACKNOWLEDGEMENTS

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

ORCID iD

Minjae Kim: https://orcid.org/0000-0001-6743-0636 Shin Hwang: https://orcid.org/0000-0002-9045-2531 Chul-Soo Ahn: https://orcid.org/0000-0002-3844-3646 Ki-Hun Kim: https://orcid.org/0000-0002-4016-0995 Deok-Bog Moon: https://orcid.org/0000-0002-8209-3540 Tae-Yong Ha: https://orcid.org/0000-0001-9932-0212 Gi-Won Song: https://orcid.org/0000-0001-9932-0212 Gi-Won Song: https://orcid.org/0000-0002-4235-0434 Dong-Hwan Jung: https://orcid.org/0000-0001-5984-023X Gil-Chun Park: https://orcid.org/0000-0003-1631-3258 Seung-Mo Hong: https://orcid.org/0000-0002-8888-6007

Author Contribution

Conceptualization, Project Administration: SH Formal Analysis: MK, SH, SMH Investigation: CSA, KHK Methodology: DBM, TYH, GWS, DHJ, GCP Writing – Original Draft: SH, MK Writing – Review & Editing: All authors

REFERENCES

- 1. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol 1949;25:647-55.
- 2. Goodman ZD, Ishak KG, Langloss JM,

Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma: a histologic and immunohistochemical study. Cancer 1985:55:124-35. Theise ND, Park YN, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon, France: IARC: 2010. p. 225-7.

- Jung DH, Hwang S, Hong SM, Chung YK, Song GW, Lee YJ, et al. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 WHO classification. World J Surg 2017;41:1347-57.
- 5. Ikeda H. Harada K. Sato Y. Sasaki M. Yoneda N. Kitamura S. et al. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol 2013; 140:329-40.
- 6. Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013;37:496-505.
- Sasaki M, Sato H, Kakuda Y, Sato Y, Choi JH, Nakanuma Y. Clinicopathological significance of 'subtypes with stemcell feature' in combined hepatocellularcholangiocarcinoma. Liver Int 2015;35: 1024-35.
- Cho HD, Hwang S, Lee YJ, Park KM, Kim KH, Kim JC, et al. Changes in the types of liver diseases requiring hepatic resection: a single-institution experience of 9.016 cases over a 10-year period. Korean J Hepatobiliary Pancreat Surg 2016;20:49-52.
- Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
- Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 2006;13:537-42.
- 11. Lee JH. Chung GE. Yu SJ. Hwang SY. Kim JS. Kim HY. et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular

carcinoma and cholangiocarcinoma. J Clin Gastroenterol 2011;45:69-75.

- 12. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, et al. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 2006;10:987-98.
- Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl 2014;20: 952-9.
- Kojiro M. Pathomorphology of advanced hepatocellular carcinoma. In: Tobe T, Kameda H, Okudaira M, Ohto M, Endo Y, Mito M, et al., editors. Primary liver cancer in Japan. Tokyo: Springer-Verlag; 1992. p. 31-37.
- Shiraishi M, Takushi Y, Simoji H, Oshiro T, Shinzato S, Tanigawa N, et al. Combined hepatocellular and cholangiocellular carcinoma in a non-cirrhotic liver. J Gastroenterol 1998;33:593-6.
- 16. Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and doublefluorescence immunostaining evidence. Histopathology 2008;52:224-32.
- 17. Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma 2018;6:11-21.
- Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol 2010;25:1485-92.
- Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003;43:263-71.
- 20. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers: clinical and biological implications. Am J

Pathol 1996;149:1167-75.

- 21. Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, et al. Genetic classification of combined hepatocellularcholangiocarcinoma. Hum Pathol 2000;31:1011-7.
- 22. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017;66:952-61.
- 23. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40:298-304.
- 24. Ariizumi S, Kotera Y, Katagiri S, Nakano M, Nakanuma Y, Saito A, et al. Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy. Ann Surg Oncol 2014;21(Suppl 3):S451-8.
- 25. Lee CH, Hsieh SY, Chang CJ, Lin YJ. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 2013;28:122-7.
- 26. De Vito C, Sarker D, Ross P, Heaton N, Quaglia A. Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series. Virchows Arch 2017;471:619-29.
- 27. Kim JH. Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010;255:270-7.
- 28. Na SK, Choi GH, Lee HC, Shin YM, An J, Lee D, et al. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. PLoS One 2018;13:e0198138.
- 29. Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 2018;109:2549-57.